Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Surprise AstraZeneca Singles Out Emerging Markets For Growth, But Japan Too?

This article was originally published in PharmAsia News

Executive Summary

Japan offers AstraZeneca a patent expiry cushion as the company tries to right itself elsewhere.

You may also be interested in...



Revamping AstraZeneca, Soriot Calls For Focus And Speedier Innovation

AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.

AstraZeneca’s Menelas Pangalos: An Interview With “The Pink Sheet” DAILY

With AstraZeneca in the midst of a major R&D overhaul, Menelas Pangalos, the company’s head of discovery research and early-stage development in small molecules, talked to “The Pink Sheet” DAILY about how the new R&D structure will improve the big pharma’s research productivity.

AstraZeneca Faces Uphill Battle In Talking U.S. Docs Into Using Brilinta

U.S. physicians say skepticism over the North American results in the pivotal PLATO study is one of many factors that’s been slowing adoption. Competition with low-cost generics is another.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142222

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel